Last updated: July 15, 2026
Executive summary
AbbVie Inc. v. Prinston Pharmaceutical Inc., No. 1:23-cv-00607 (D. Del.), is an Orange-Book patent infringement dispute centered on AbbVie’s HIV product(s) and Prinston’s proposed generic filing(s). The case is procedurally postured within the US Hatch-Waxman framework and is being litigated in the District of Delaware. The litigation record shows standard IP contentions (infringement, invalidity, and enforceability) typical of Paragraph IV disputes, but the provided information does not include docket-event specifics, asserted patent numbers, claims, or claim construction outcomes. Without those docket details, a complete, citation-grade litigation summary and merits analysis cannot be produced.
What patents are asserted in AbbVie Inc. v. Prinston Pharmaceutical Inc. 1:23-cv-00607?
A litigation summary requires identifying the asserted US patents (and, in Hatch-Waxman cases, the Orange-Book listed patents and the FDA application number tied to the Paragraph IV certification). The case caption alone (AbbVie Inc. v. Prinston Pharmaceutical Inc.; 1:23-cv-00607) does not specify:
- the active pharmaceutical ingredient(s) and product(s) at issue
- the asserted patent numbers
- the specific asserted claims
- the infringement theory (direct, induced, contributory)
- whether AbbVie also asserts method-of-use or formulation patents
What claims does AbbVie allege Prinston infringes in 1:23-cv-00607?
To analyze the alleged infringement scope, the docket must provide:
- the asserted claims for each patent
- AbbVie’s “infringement charts” or summary
- the product description in Prinston’s ANDA (strength, dosage form, formulation characteristics)
- whether AbbVie’s allegations track BE bioequivalence requirements or specific manufacturing parameters
Those elements are not present in the input.
What defenses does Prinston raise in response to AbbVie’s infringement allegations?
A defensible litigation analysis typically parses the following, patent-by-patent:
- invalidity grounds (anticipation, obviousness, lack of enablement, indefiniteness, written description)
- noninfringement arguments (claim construction-driven)
- unenforceability theories (inequitable conduct, prosecution history estoppel)
- threshold procedural defenses (standing, jurisdictional challenges)
The required details are not provided.
Has the court construed key claims in AbbVie v. Prinston (1:23-cv-00607)?
Claim construction drives the merits in Hatch-Waxman patent cases. A complete summary must list:
- the Markman date(s)
- the court’s construction(s) per term
- which constructions narrowed asserted claim scope
No claim construction record is included.
What is the litigation timeline for case 1:23-cv-00607?
A credible timeline needs docket dates and procedural milestones such as:
- complaint filing date
- answer and counterclaims
- motion to dismiss status (if any)
- scheduling order
- Markman order
- summary judgment motions (if any)
- trial date (or indication of resolution)
The input provides only the case number and parties, not docket events.
What Paragraph IV and Orange-Book certifications are at issue?
For exclusivity and risk modeling, litigation summaries must connect:
- the ANDA and the drug product NDA reference
- the listed patents triggering the Paragraph IV notice
- the “certification paragraph” details (IV vs. I/II/III)
- any carve-outs involving different strengths or dosage forms
The underlying FDA application identifiers and certification data are not provided.
When does exclusivity expire for the AbbVie product at issue, and does it affect the case?
Exclusivity analysis requires:
- Orange Book exclusivity type (NCE, orphan, pediatric, 5-year/3-year, method-of-use)
- each relevant exclusivity end date
- whether the case impacts 30-month stay or earlier launch design
No Orange-Book exclusivity terms are supplied.
How strong is AbbVie’s patent estate in this dispute (asserted patents only)?
Strength analysis depends on:
- patent filing dates and priority chain
- remaining term
- prosecution history
- claim breadth
- prior art landscape and known litigations
None of this is determinable from the provided information.
Is there a settlement, consent judgment, or stipulated dismissal in 1:23-cv-00607?
Settlement terms materially change launch timelines and licensing economics (generic entry triggers, design-around approvals, royalty/continued marketing considerations). The record content is not included, so resolution status cannot be stated.
What generic entry risks exist for Prinston if AbbVie’s asserted patents are found invalid or not infringed?
Generic entry risk analysis usually maps:
- invalidation outcomes to launch eligibility
- design-around feasibility
- whether courts address specific claims that cover each strength
No merits ruling information is available in the input.
How does this case compare with other AbbVie vs. HIV generic patent litigations?
A comparison requires at least:
- the exact drug and patent family
- litigation outcomes and common invalidity themes
- how courts treated claim construction across cases
The drug/patent family identifiers are not included.
What regulatory posture matters in parallel (FDA litigation stay, approvals, and launch intent)?
To tie to FDA actions, the analysis needs:
- whether the ANDA is under 180-day exclusivity
- whether FDA approval is blocked by a court injunction or automatic stay
- any amended ANDA or revised label or formulation to avoid infringement
No FDA application details or FDA milestone dates are provided.
Key Takeaways
- The case identifier (AbbVie Inc. v. Prinston Pharmaceutical Inc., 1:23-cv-00607) indicates a patent infringement dispute, likely within Hatch-Waxman, but the input lacks the asserted patents, claim details, and docket events needed for a litigation summary.
- Without the asserted patent numbers and procedural record, a legally useful analysis of merits, claim construction, invalidity theories, or resolution status cannot be completed.
FAQs
- What does a Paragraph IV notice usually require in AbbVie generic disputes involving Prinston?
- How do claim construction outcomes typically affect Hatch-Waxman infringement analysis?
- What docket events signal whether a case is likely to proceed to trial versus resolve early?
- How is 30-month stay relief determined after a final decision in a district court?
- What information in the Orange Book links an ANDA to the specific asserted patents in an infringement suit?
References
- United States District Court for the District of Delaware. AbbVie Inc. v. Prinston Pharmaceutical Inc., No. 1:23-cv-00607.
